Previous 10 | Next 10 |
SAN FRANCISCO, CA / ACCESSWIRE / March 1, 2024 / Hagens Berman urges BioVie Inc. (NASDAQ:BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 - Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: www.hbsslaw.com/investor-frau...
BioVie Inc. (NASDAQ: BIVI) is one today's most active stocks by volume. So far today, approximately 76.7M shares of BioVie Inc. have been exchanged, as compared to an average 30-day volume of 124.01k shares. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, develop...
Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened Data from Phase 3 trial in mild to moderate Alzheimer’s Disease sug...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and...
SAN FRANCISCO, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: www...
Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and...
SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: www...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and...
SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: www...
News, Short Squeeze, Breakout and More Instantly...
BioVie Inc. Company Name:
BIVI Stock Symbol:
OTCMKTS Market:
CARSON CITY, Nev., June 12, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing...
CARSON CITY, Nev., June 12, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is ...
CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, tod...